Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later

Urology

Volumn 73, Issue 5 SUPPL., 2009, Pages

  Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; COST-BENEFIT ANALYSIS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 64349085626     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.02.016     Document Type: Article

References (83)

1. Loeb S., and Catalona W.J. What to do with an abnormal PSA test. Oncologist 13 (2008) 299-305
2. Cooner W.H., Mosley B.R., Rutherford Jr. C.L., et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143 (1990) 1146-1152
3. Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 25 (1995) 289-294
4. Ulmert D., Cronin A.M., Bjork T., et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6 (2008) 6-13
5. Hara M., Inoue T., and Koyanagi Y. Preparation and immunoelectrophoretic assessment of antisera to human seminal plasma. Nippon Hoigaku Zasshi 20 (1996) 365
6. Wang M.C., Valenzuela L.A., Murphy G.P., et al. Purification of a human prostate specific antigen: 1979 [classical article]. J Urol 167 (2002) 1226-1230
7. Gutman A.B., and Gutman E.B. An "acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 17 (1938) 473-478
8. Bensalah K., Lotan Y., Karam J.A., et al. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 11 (2008) 112-120
9. Scardino P.T. The Gordon Wilson lecture: natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc 111 (2000) 201-241
10. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 150 (1993) 100-105
11. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41-45
12. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60 (2000) 756-759
13. Mikolajczyk S.D., Catalona W.J., Evans C.L., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50 (2004) 1017-1025
14. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 6 Pt. 1 (2004) 2239-2244
15. Lee F., Torp-Pedersen S.T., Siders D.B., et al. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 170 3 Pt. 1 (1989) 609-615
16. Mettlin C., Murphy G.P., Lee F., et al., Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Characteristics of prostate cancers detected in a multimodality early detection program. Cancer 72 (1993) 1701-1708
17. Littrup P.J., Lee F., and Mettlin C. Prostate cancer screening: current trends and future implications. CA Cancer J Clin 42 (1992) 198-211
18. Lowe F.C., and Trauzzi S.J. Prostatic acid phosphatase in 1993: its limited clinical utility. Urol Clin North Am 20 (1993) 589-595
19. Makarov D.V., and Carter H.B. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol 176 6 Pt. 1 (2006) 2383-2385
20. Romero F.R., Romero K.R., Brenny F.T., et al. Reasons why patients reject digital rectal examination when screening for prostate cancer. Arch Esp Urol 61 (2008) 759-765
21. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
22. Borden Jr. L.S., Wright J.L., Kim J., et al. An abnormal digital rectal examination is an independent predictor of Gleason ≥7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int 99 (2007) 559-563
23. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
24. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
25. Hernandez D.J., Han M., Humphreys E.B., et al. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int 103 (2009) 609-614
26. Brawer M.K., Beatie J., Wener M.H., et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 150 (1993) 106-109
27. Brawer M.K., Chetner M.P., Beatie J., et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 147 3 Pt. 2 (1992) 841-845
28. Terris M.K., and Stamey T.A. Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. Br J Urol 73 (1994) 61-64
29. Hernández J., and Thompson I.M. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101 (2004) 894-904
30. Henkel J. Prostate cancer: new tests create treatment dilemmas. FDA Consumer (December 1994). http://www.fda.gov/fdac/reprints/prostate.html Updated 1997. Accessed December 16, 2008
31. Welch H.G., Schwartz L.M., and Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 97 (2005) 1132-1137
32. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131
33. Bartsch G., Horninger W., Klocker H., et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101 (2008) 809-816
34. Carter H.B., Morrell C.H., Pearson J.D., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52 (1992) 3323-3328
35. D'Amico A.V., and Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72 (1993) 2638-2643
36. Carter H.B., and Pearson J.D. PSA velocity for the diagnosis of early prostate cancer: a new concept. Urol Clin North Am 20 (1993) 665-670
37. Lilja H., Ulmert D., and Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8 (2008) 268-278
38. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
39. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335 (1996) 304-310
40. Evans S., Metcalfe C., Ibrahim F., et al. Differences in prostate cancer prognosis: a systematic review and metal-analysis. Int J Cancer 123 (2008) 430-435
41. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452-1455
42. Punglia R.S., D'Amico A.V., Catalona W.J., et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349 (2003) 335-342
43. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
44. Andriole G.L., Roehrborn C., Schulman C., et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (2004) 537-541
45. Guess H.A., Heyse J.F., Gormley G.J., et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American phase III clinical trial. Urol Clin North Am 20 (1993) 627-636
46. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128-1133
47. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 4 Pt. 1 (2004) 1314-1317
48. Oesterling J.E. Prostate-specific antigen and diagnosing early malignancies of the prostate. J Cell Biochem Suppl 16H (1992) 31-43
49. el-Shirbiny A.M. Prostatic specific antigen. Adv Clin Chem 31 (1994) 99-133
50. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
51. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer early detection. V.2 (2007). http://www.nccn.org Updated May 10, 2007. Accessed December 24, 2008
52. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
53. Ashley T. Using predictive value, sensitivity and specificity to interpret laboratory tests: PSA for the diagnosis of prostate cancer. J Insur Med 37 (2005) 261-263
54. Klein L.T., and Lowe F.C. The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am 24 (1997) 293-297
55. Erdogan K., Gurdal M., Tekin A., et al. The effect of urethral catheterisation on serum prostate-specific antigen levels in male patients with acute urinary retention. Yonsei Med J 44 (2003) 676-678
56. Parekh N., Lin Y., Marcella S., et al. Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev 17 (2008) 2467-2472
57. Bangma C.H., Roemeling S., and Schröder F.H. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25 (2007) 3-9
58. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
59. Thompson I.M., and Ankerst D.P. Prostate-specific antigen in the early detection of prostate cancer. Can Med Assoc J 176 (2007) 1853-1858
60. American Cancer Society. Cancer facts and figures 2008. http://www.cancer.org/docroot/stt/stt_0.asp Accessed December 9, 2008
61. Tarone R.E., Chu K.C., and Brawley O.W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11 (2000) 167-170
62. Bouchardy C., Fioretta G., Rapiti E., et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 123 (2008) 421-429
63. Clements A., Watson E., Rai T., et al. The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study. BMC Fam Pract 8 (2007) 35-41
64. Ekwueme D.U., Stroud L.A., and Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis 4 (2007) A100-A116
65. Prorok P.C., Andriole G.L., Bresalier R.S., et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21 suppl (2000) 273S-309S
66. Zoorob R., Anderson R., Cefalu C., and Sidani M. Cancer screening guidelines. Am Fam Physician 63 (2001) 1101-1112
67. Andriole G.L., Levin D.L., Crawford E.D., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97 (2005) 433-438
68. Schröder F.H. Screening for prostate cancer (PC)-an update on recent findings of the European Randomised Study of Screening for Prostate Cancer (ERSPC). Urol Oncol 26 (2008) 533-541
69. Roobol M.J., Roobol D.W., and Schröder F.H. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting?. (ERSPC, section Rotterdam). Urology 65 (2005) 343-346
70. U.S. Preventive Services Task Force recommendation statement. Screening for prostate cancer. Ann Intern Med 149 (2008) 185-191
71. Lin K., Lipsitz R., Miller T., et al. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 149 (2008) 192-199
72. Davidov O., and Zelen M. Overdiagnosis in early detection programs. Biostatistics 5 (2004) 603-613
73. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981-990
74. Taichman R.S., Loberg R.D., Mehra R., et al. The evolving biology and treatment of prostate cancer. J Clin Invest 117 (2007) 2351-2361
75. Graif T., Loeb S., Roehl K.A., et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 178 (2007) 88-92
76. Pelzer A.E., Bektic J., Akkad T., et al. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml. J Urol 178 (2007) 93-97
77. Penson D.F., Schonfeld W.H., Flanders S.C., et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CaPSURE database. Urology 57 (2001) 499-503
78. Barry M.J., Fleming C., Coley C.M., et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer?. Part IV: estimating the risks and benefits of an early detection program. Urology 46 (1995) 445-461
79. Coley C.M., Barry M.J., Fleming C., et al. Early detection of prostate cancer. Part II: estimating the risks, benefits, and costs. Ann Intern Med 126 (1997) 468-479
80. Crawford E.D., and Abrahamsson P.A. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?. Eur Urol 54 (2008) 262-273
81. Harris R., and Lohr K.N. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 (2002) 917-929
82. Andriole G.L., Grubb III R.L., Buys S.S., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009) 1310-1319
83. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328